- Current report filing (8-K)
April 01 2011 - 6:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): April 1,
2011 ( March 31, 2011)
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation
or organization)
|
|
|
No. 14 East Hushan Road,
Tai'an City, Shandong, 271000
People's Republic of China
(Address of Principal Executive Offices)
86-538 -620-2306
Registrant's telephone number, including area code
____________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 2.02 Results of Operations and Financial
Condition
On March 31, 2011, China Biologic Products, Inc. (the
"Company") issued a press release announcing its financial results for its
fiscal year ended December 31, 2010. A copy of the press release, which the
Company is furnishing to the Securities and Exchange Commission, is attached as
Exhibit 99.1 and incorporated by reference herein.
The information contained in this Current Report on Form 8-K
and the exhibits attached hereto shall not be deemed to be "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall such
information or such exhibits be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure.
The information set forth in Item 2.02 above is incorporated
by reference herein.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Date: March 31, 2011
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
By: /s/ Chao Ming Zhao
|
|
Chao Ming Zhao
|
|
Chief Executive Officer
|
- 3 -
EXHIBIT INDEX
- 4 -
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024